Alexion Pharmaceuticals Announces Presentation of Soliris Data at ASH

Alexion Pharmaceuticals

today announced that researchers presented data from clinical trials demonstrating the clinical benefits of chronic Soliris® (eculizumab) treatment in patients with atypical hemolytic uremic syndrome (aHUS) as well as new patient registry data providing further insight into optimal care for patients with paroxysmal nocturnal hemoglobinuria (PNH) at the American Society of Hematology (ASH) 55th Annual Meeting and Exposition in New Orleans. Data included: A new, comprehensive study of key aHUS biomarkers indicating that, prior to initiation of Soliris treatment, aHUS patients have severe ongoing terminal complement activation and inflammation with increased thrombotic risk. The study further indicates